Warner Greene, MD, PhD

Headshot of Warner Greene
User Profile Photo

Warner Greene, MD, PhD

User Profile Name
Director, Gladstone Center for HIV Cure Research
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science. He also serves as Co-Director of the UCSF-Gladstone Center for AIDS Research, and has served as a Councilor and President of the Association of American Physicians. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as the Founding Director of the Gladstone Institute of Virology and Immunology in 1991. The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying HIV pathogenesis, latency, and transmission. He is the author of more than 380 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. In 2007, Dr. Greene expanded his work to include global health in sub-Saharan Africa in his service as president and executive chairman of the Accordia Global Health Foundation. Accordia established the Infectious Diseases Institute at Makerere University in Uganda, which has trained thousands of African health care workers, is caring for 30,000 HIV-infected patients, and has brought health care to nearly 500,000 people living in remote rural regions of Uganda. In 2016, Accordia merged with Africare.
CTSI Profile Bio

Displaying 151 - 175 of 386

  1. Sherman MP, De Noronha CM, Williams SA, Greene WC. Insights into the biology of HIV-1 viral protein R. DNA Cell Biol. 2002 Sep; 21(9):679-88.
  2. Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med. 2002 Jul; 8(7):673-80.
  3. Sherman MP, Greene WC. Slipping through the door: HIV entry into the nucleus. Microbes Infect. 2002 Jan; 4(1):67-73.
  4. Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Goldsmith MA. HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med. 2001 Nov 19; 194(10):1407-19.
  5. de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, Goldman RD, Greene WC. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science. 2001 Nov 02; 294(5544):1105-8.
  6. Chen Lf , Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001 Aug 31; 293(5535):1653-7.
  7. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature. 2001 Apr 12; 410(6830):834-8.
  8. Schaeffer E, Geleziunas R, Greene WC. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol. 2001 Mar; 75(6):2993-3000.
  9. Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC. Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol. 2001 Feb; 75(3):1522-32.
  10. Foehr ED, Bohuslav J, Chen LF, DeNoronha C, Geleziunas R, Lin X, O'Mahony A, Greene WC. The NF-kappa B-inducing kinase induces PC12 cell differentiation and prevents apoptosis. J Biol Chem. 2000 Nov 03; 275(44):34021-4.
  11. Foehr ED, Lin X, O'Mahony A, Geleziunas R, Bradshaw RA, Greene WC. NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells. J Neurosci. 2000 Oct 15; 20(20):7556-63.
  12. Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, de Noronha CM, Greene WC, Wray V, Schubert U. Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J Biol Chem. 2000 Oct 13; 275(41):32016-26.
  13. Lin L, DeMartino GN, Greene WC. Cotranslational dimerization of the Rel homology domain of NF-kappaB1 generates p50-p105 heterodimers and is required for effective p50 production. EMBO J. 2000 Sep 01; 19(17):4712-22.
  14. Sherman MP, de Noronha CM, Pearce D, Greene WC. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol. 2000 Sep; 74(17):8159-65.
  15. Lin X, O'Mahony A, Mu Y, Geleziunas R, Greene WC. Protein kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta. Mol Cell Biol. 2000 Apr; 20(8):2933-40.
  16. O'Mahony A, Lin X, Geleziunas R, Greene WC. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol. 2000 Feb; 20(4):1170-8.
  17. Heusch M, Lin L, Geleziunas R, Greene WC. The generation of nfkb2 p52: mechanism and efficiency. Oncogene. 1999 Nov 04; 18(46):6201-8.
  18. Bresnahan PA, Yonemoto W, Greene WC. Cutting edge: SIV Nef protein utilizes both leucine- and tyrosine-based protein sorting pathways for down-regulation of CD4. J Immunol. 1999 Sep 15; 163(6):2977-81.
  19. Lin X, Cunningham ET, Mu Y, Geleziunas R, Greene WC. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases. Immunity. 1999 Feb; 10(2):271-80.
  20. Jenkins Y, McEntee M, Weis K, Greene WC. Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways. J Cell Biol. 1998 Nov 16; 143(4):875-85.
  21. Bresnahan PA, Yonemoto W, Ferrell S, Williams-Herman D, Geleziunas R, Greene WC. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr Biol. 1998 Nov 05; 8(22):1235-8.
  22. Lin X, Mu Y, Cunningham ET, Marcu KB, Geleziunas R, Greene WC. Molecular determinants of NF-kappaB-inducing kinase action. Mol Cell Biol. 1998 Oct; 18(10):5899-907.
  23. Liegler TJ, Yonemoto W, Elbeik T, Vittinghoff E, Buchbinder SP, Greene WC. Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors. J Infect Dis. 1998 Sep; 178(3):669-79.
  24. Geleziunas R, Ferrell S, Lin X, Mu Y, Cunningham ET, Grant M, Connelly MA, Hambor JE, Marcu KB, Greene WC. Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases. Mol Cell Biol. 1998 Sep; 18(9):5157-65.
  25. Lin L, DeMartino GN, Greene WC. Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. Cell. 1998 Mar 20; 92(6):819-28.